Similar results were seen in an ALK+ ALCL patient treated with imatinib [36], which though developed as a BCR-ABL kinase inhibitor also inhibits enzymatic activity of PDGFRA, PDGFRB, and c-KIT kinases Importantly, PDGFRB was shown to be a direct target of JUN/JUNB complex downstream of NPM-ALK, and imatinib efficacy was shown to have a positive correlation with PDGFRB expression in mice bearing ALK+ ALCL tumors [36]. Here, NPM1 is linked to anaplastic large cell lymphoma.